The ability of the inflammatory microenvironment to promote tumor development is based on the evidence that chronic inflammatory diseases increase the risk for some types of cancers (including bladder, cervical, gastric, intestinal, esophageal, ovarian, prostate, and thyroid cancers); this oncogenic promotion is linked to pathways that are activated in inflammatory processes by mutations in oncogenes (such as mutations in the genes encoding RAS and MYC); furthermore, inflammatory cells, chemokines, and cytokines are found in all tumors from the early stages of their development [155]. This evidence concerns the gene MYC and neoplasm.